Intravenous Iron in Heart Failure Patients With Iron Deficiency: A Meta‐Analysis of Randomized Controlled Trials
For HF patients with ID, intravenous iron therapy can decrease the risk of hospitalization for HF, CV death and improve their exercise capacity. Patients with ischemic cardiomyopathy or with TSAT <20% may derive greater benefit from intravenous iron therapy.
Authors
- Ling Zhao (ORCID: https://orcid.org/0000-0002-4017-8167)
- Xiaomei Zhang (ORCID: https://orcid.org/0000-0002-2367-9840)
- Lingxiao Li (ORCID: https://orcid.org/0000-0001-5571-5968)
- Yangguang Liu (ORCID: https://orcid.org/0000-0002-2364-3055)
- Yingwen Chen (ORCID: https://orcid.org/0000-0001-7282-6969)
- Jiahuan Li (ORCID: https://orcid.org/0009-0009-3978-3456)
Institutions
- The First People's Hospital of Shunde (CN)
- The George Institute for Global Health (AU)
Publication Details
- Journal
- Journal of Evidence-Based Medicine
- Published
- 2025-08-14
- DOI
- https://doi.org/10.1111/jebm.70057
- Citations
- 1
- Primary Topic
- Erythropoietin and Anemia Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.77
Funders
- National Natural Science Foundation of China
- Southern Medical University
- Guangzhou Municipal Science and Technology Project